Assessment of heart muscle damage secondary to coronavirus disease (COVID-19) in a hospitalised-recovering patient population (or those recently discharged) with raised cardiac biomarkers (troponin) Infections and Infestations COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
Current interventions, as of 10/05/2021:
Firstly, we will establish a de-identified national image repository for all heart MRI scans already performed clinically in patients with COVID-19 infection
Sponsors
University of Leeds
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged = 18 years 2. Diagnosed with SARS-CoV-2 infection with a raised cardiac biomarker (Troponin)
Exclusion criteria
Exclusion criteria: 1. Unable/unwilling to consent 2. Significant renal impairment (eGFR<30ml/min/m²) 3. Female participants who are pregnant, lactating or planning pregnancy during the course of the study 4. Contraindications to MRI (pacemaker, intra-orbital debris, intra-orbital debris, intra-auricular implants, intracranial clips, severe claustrophobia 5. Known hypersensitivity to gadolinium-based contrast agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of COVID-19 on the heart at baseline and 6 months: 1. Heart abnormalities assessed using MRI 2. Heart rhythm and electrical activity assessed using ECG 3. Walking ability assessed using 6-min walking test 4. Patient-reported health status assessed using SF-36 5. Health-related quality of life assessed using EQ-5D | — |
Secondary
| Measure | Time frame |
|---|---|
| The influence of comorbidities, age, and genetics measured using medical records monitored from baseline up to 1 year (an optional blood test will be performed at baseline for genetic and immunological testing) | — |
Countries
England, Scotland, United Kingdom, Wales
Contacts
Public ContactKathryn;Laura Somers;Jones
;
Outcome results
None listed